Market Research Report Store Actinomycosis-Global API Manufacturers, Marketed a | Page 2

• A review of the marketed products under prescription for Actinomycosis, regulatory information and
marketing status.
• Coverage of global patent coverage and detailed commentaries on the US patent challenges.
• Graphical representation of investigational products for patent expiry and market exclusivities across
the globe.
• Product profiles for marketed products for Actinomycosis with complete description of mechanism of
action, therapeutic class, target, route(s) of administration and chemical details.
• Coverage of API Manufacturers for Actinomycosis drugs in the United States, Europe and Asian
Regions with location details.
• Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for
Actinomycosis drugs.
• Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Actinomycosis
drugs.
• Coverage of Actinomycosis Phase III pipeline products featuring sections on product description,
mechanism of action, Chemical details and research & development progress.
• Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
• Key discontinued Marketed products.
• Global Sales Figure to 2018.
Reasons to buy
• Evaluate the marketing status and exclusivity details of Actinomycosis key products to exploit
opportunities for generic drug development opportunities.
• Identify and understand important and diverse types of therapeutics under Phase III development for
Actinomycosis.
• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry
details and exclusivity with respect to Actinomycosis.
• API intelligence over marketed drugs forActinomycosisand gaining primary intelligence over active
ingredients manufacturers across the globe.
• API intelligence over leading Phase III Pipeline drugs.